This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:

"New research suggests that a low-calorie diet might help reverse symptoms of type 2 diabetes in men with obesity. The findings of the study add to a growing body of evidence indicating that diabetes is a reversible condition. Authors of the study looked at 18 men in South Africa who were over the age of 35, had class III obesity, and were on insulin treatment for diabetes. The participants were randomized to one of two groups: one followed a commercially available low-fat, low-calorie diet consisting of vegetables and a vegetable-soup-based meal plan; while the control group received a calorie-restricted meal plan. All participants were encouraged to engage in physical activity according to their abilities and to visit a counseling psychologist at least once a month. Over the course of 6 months, the team tracked the men’s levels of blood glucose and glycated hemoglobin, or HbA1c—using those measures to establish diabetes status..."

The rest of the transcript, along with a link to the research itself, is available on the resource itself.

Biology is designed for multi-semester biology courses for science majors. It is grounded on an evolutionary basis and includes exciting features that highlight careers in the biological sciences and everyday applications of the concepts at hand. To meet the needs of today’s instructors and students, some content has been strategically condensed while maintaining the overall scope and coverage of traditional texts for this course. Instructors can customize the book, adapting it to the approach that works best in their classroom. Biology also includes an innovative art program that incorporates critical thinking and clicker questions to help students understand—and apply—key concepts.

By the end of this section, you will be able to:Explain how hormones regulate the excretory systemDiscuss the role of hormones in the reproductive systemDescribe how hormones regulate metabolismExplain the role of hormones in different diseases

This patient education program explains what diabetes is, the signs and symptoms, treatment options, hyperglycemia and hypoglycemia, complications, and management of the disease. This resource is a MedlinePlus Interactive Health Tutorial from the National Library of Medicine, designed and developed by the Patient Education Institute.

This presentation discusses the possibility of finding a cure for type 1 diabetes, and hereby developing a product, that maintains a normal blood glucose level without insulin treatment. In continuation of this, we’ll provide an introduction to beta cell replacement therapy based on The Edmonton Protocol, however we’ll be focusing on relying on stem cell technology rather than that of organ donor islets. Furthermore we’ll discuss how we can combine an encapsulation strategy, so we can avoid the use of immuno-suppression.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

In this presentation aim to increase the student’s knowledge about translational metabolism, in continuation of this we’ll elaborate on topics related to food ingestion, bone resorption, the intestinale hormone GIP, genetic variation in the receptor of GIP in relation to fracture risk, food availability and bone regulation, blood glucose and future treatment of osteoporosis.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This presentation provides an introduction to Sodium-glucose linked transporter 2 inhibitors (SGLT-2) and how it affects the blood glucose. Furthermore we’ll discuss how SGLT-2 inhibitors can be used for treating patients with type 2 diabetes. Three SGLT-2 inhibitors have been approved: Dapa, Empa and Canagliflozin, for clinical use in patients with type 2 diabetes.

Course responsible: Associate Professor Signe Sørensen Torekov, MD Nicolai Wewer Albrechtsen & Professor Jens Juul Holst

This patient education program explains what diabetes is, the signs and symptoms, treatment options, hyperglycemia and hypoglycemia, complications, and management of the disease. This resource is a MedlinePlus Interactive Health Tutorial from the National Library of Medicine, designed and developed by the Patient Education Institute.

This presentation provides an introduction to Diabetes.What is diabetes and what happens in the body? You will learn how diabetes is a term used to describe the body’s inability to produce sufficient amounts of insulin and how insulin as a pancreatic hormone functions as a main glucose regulator, that makes sure our glucose levels are balanced. Both high and low blood glucose levels are dangerous. When you have diabetes, the lack of insulin will cause high blood glucose levels, which affects several parts of your body.

Narrator: Richard Steed.

In this presentation you will learn about the evolution of diabetes and how it affects the world population. Diabetes is probably recognized as one of the biggest global health challenges in the 21st century. Figures from 2012 shows that diabetes caused the death of 1.5 million people and lead to an additional 2.2 million deaths caused by higher than optimal blood glucose, which increases the risk of cardiovascular and other diseases. The prevalence of diabetes is rising in all income groups, however over the past decade it has risen faster in low and middle income countries rather than in high income countries.

Narrator: Richard Steed.

This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:

"Diseases like epilepsy and diabetes are linked to inflammation and oxidative stress which can be further complicated by persistent high blood glucose levels Drug-based treatments can help, but issues of tolerance, effectiveness, and compliance can complicate treatment The ketogenic diet (KD) reduces blood glucose and insulin, helping individuals to manage their condition But adherence to a strict KD can be difficult A recent study at the University of South Florida identified a promising possible alternative to KD adherence Using rodent models of epilepsy and glucose intolerance as well as non-disease models Researchers evaluated blood glucose levels after administration of exogenous ketone supplements Animals given exogenous ketones had lower blood glucose levels, both when resting and after exercise This treatment was effective for all of the disease models evaluated, and it also helped reduce blood glucose in rodents without pathology at different age ranges Further preclinical and clin.."

The rest of the transcript, along with a link to the research itself, is available on the resource itself.

After studying the basics of enzyme function, students will be exposed to the history and evolution of lactose intolerance/lactase persistence. Both whole group and individual activities will ask students to interact with the concept. They will conduct a lab to understand the role of enzymes in lactose digestion and communicate their knowledge by creating a public health poster.

After studying the basics of enzyme function, students will be exposed to the history and evolution of lactose intolerance/lactase persistence. Both whole group and individual activities will ask students to interact with the concept. They will conduct a lab to understand the role of enzymes in lactose digestion and communicate their knowledge by creating a public health poster.

This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:

"Diabetes and chronic kidney disease are common comorbid conditions, with reports suggesting that chronic kidney disease affects up to half of all patients with type 2 diabetes. Renal impairment complicates the management of diabetes because it increases the risk of heart disease and excessively low blood glucose levels called hypoglycemia. These risks limit the options for glucose-lowering treatment. Insulin remains a viable treatment option for people with diabetes and chronic kidney disease. However, there is limited data from large studies that compare how different insulins impact treatment outcomes in this patient population. A recent patient-level meta-analysis of the phase III EDITION trials helps bridge this data gap by investigating the impact of renal function on the safety and efficacy of insulin glargine 100 versus the newer insulin glargine 300..."

The rest of the transcript, along with a link to the research itself, is available on the resource itself.

This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:

"Hypoglycemia, or low blood glucose, is an important risk factor for people with type 2 diabetes receiving blood glucose-lowering therapies, such as insulin. It can lead to symptoms that interfere with activities of daily living and can sometimes (though rarely) result in debilitating events, including loss of consciousness. Basal insulins are designed to help maintain stable blood glucose levels throughout the day. Data from randomized clinical trials show that newer, second-generation basal insulin analogs (such as insulin glargine 300 units per mL and insulin degludec) have lower hypoglycemia risk than first- generation basal insulin analogs (such as insulin glargine 100 units per mL and insulin detemir), while providing comparable glycemic control. However, these randomized controlled trials may not truly reflect clinical practice, as they applied strict inclusion and exclusion criteria and were conducted under strict oversight dictated by very specific protocols..."

The rest of the transcript, along with a link to the research itself, is available on the resource itself.